A0772412
AN-2690 , ≥98.0% , 174671-46-6
Synonym(s):
1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole;5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole;AN2690;AN-2690
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB39.20 | In Stock |
|
| 10MG | RMB47.20 | In Stock |
|
| 50MG | RMB55.20 | In Stock |
|
| 100MG | RMB64.00 | In Stock |
|
| 250mg | RMB89.60 | In Stock |
|
| 1g | RMB230.40 | In Stock |
|
| 5g | RMB1023.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 120-122℃ |
| Boiling point: | 230.8±50.0 °C(Predicted) |
| Density | 1.28±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 6.81±0.20(Predicted) |
| form | powder |
| color | white to beige |
| Stability: | Hygroscopic |
Description and Uses
Tavaborole (Kerydin®), discovered and developed by Anacor, was approved by the US FDA in July 2014. Tavaborole, topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. The mechanism of action of tavaborole is inhibition of fungal protein synthesis, which inhibits an aminoacyl-transfer ribonucleic acid synthetase.
Tavaborole is a topical treatment of toenail onychomycosis.
Safety
| Symbol(GHS) |   GHS07,GHS05 |
| Signal word | Danger |
| Hazard statements | H315-H312-H318-H302-H332 |
| Precautionary statements | P280-P305+P351+P338-P310-P261-P271-P304+P340-P312-P264-P280-P302+P352-P321-P332+P313-P362-P280-P302+P352-P312-P322-P363-P501-P264-P270-P301+P312-P330-P501 |
| HS Code | 2934999090 |
| Hazardous Substances Data | 174671-46-6(Hazardous Substances Data) |
